Exchange: NASDAQ·Updated 04:10 PM EST

VALN News

News
all
press releases
Full Transcript: Valneva Q2 2026 Earnings Call
Valneva (NASDAQ:VALN) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive financial data andread more...
Benzinga
Full Transcript: Valneva Q2 2026 Earnings Call
Valneva (NASDAQ:VALN) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive financial data andread more...
Benzinga
More News
Valneva said the Medicines and Healthcare products Regulatory Agency withdrew the U.K. authorization for IXCHIQ on Wednesday.
Stocktwits
Gainers Valneva (NASDAQ:VALN) shares rose 20.6% to $7.09 during Wednesday's after-market session. The company's market cap stands at $555.6 million. Profound Medical (NASDAQ:PROF) stock rose 16.98% to $6.64.read more...
Benzinga
The European Medicines Agency validated the marketing authorization application for Valneva’s Lyme disease vaccine, which it developed with Pfizer
Stocktwits
Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the companies 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate...
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN...
PR Newswire
Wall Street Zen lowered shares of Valneva to a "strong sell" rating in a research report on Saturday...
MarketBeat
Valneva (NASDAQ:VALN) Reaches New 12-Month Low Following Analyst Downgrade...
MarketBeat
Shares of Valneva SE Sponsored ADR (NASDAQ:VALN - Get Free Report) have been assigned a consensus recommendation of "Hold" from the five brokerages that are currently covering the company, MarketBeat...
MarketBeat
The Goldman Sachs Group lowered Valneva from a "neutral" rating to a "sell" rating and set a $4.90 price target on the stock. in a report on Wednesday...
MarketBeat

Advertisement|Remove ads.